Literature DB >> 26983703

Convenient Preparation of [(68)Ga]DKFZ-PSMA-11 Using a Robust Single-Vial Kit and Demonstration of Its Clinical Efficacy.

Drishty Satpati1, Ajit Shinto2, K K Kamaleshwaran2, Surekha Sane3, Sharmila Banerjee4.   

Abstract

PURPOSE: [(68)Ga]DKFZ-PSMA-11 has proved to be an important diagnostic radiotracer for targeting prostate-specific membrane antigen (PSMA) overexpression in both recurrent prostate cancer (PC) and relevant metastatic sites. However, the widespread, routine clinical use of such a potential radiopharmaceutical demands availability of a ready-to-use kit formulation to enable convenient radiopharmaceutical preparation. Herein, we report the development of a freeze-dried kit vial for the formulation of [(68)Ga]DKFZ-PSMA-11 and its clinical use in patients using a "shake-bake-inject" methodology. PROCEDURES: The freeze-dried kit vial was developed after optimization of ligand content (PSMA-11) and pH conditions. The kit was formulated using (68)Ga from two different commercially available generators. Positron emission tomography/X-ray computed tomography (PET/CT) images of PC patients were obtained using the kit-formulated radiotracer.
RESULTS: [(68)Ga]DKFZ-PSMA-11 was prepared in >98 % radiochemical yield and purity using the freeze-dried kit vials. Kits were optimized for the preparation of four patient doses. The clinical utility was evaluated in patients with histologically confirmed prostate cancer, and the images were of good quality as well as conforming to tumor marker and clinical expectations.
CONCLUSION: The development of a simple and ready-to-use freeze-dried DKFZ-PSMA-11 kit for the preparation of Ga-68-based radiotracers constitutes a major step towards the expedition of the widespread and economical screening of PC patients.

Entities:  

Keywords:  Freeze-dried kits; PET/CT; Prostate cancer; Prostate-specific membrane antigen (PSMA); [68Ga]DKFZ-PSMA-11

Mesh:

Substances:

Year:  2016        PMID: 26983703     DOI: 10.1007/s11307-016-0943-z

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  29 in total

1.  99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals.

Authors:  S Liu; D S Edwards
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.

Authors:  Shankar Vallabhajosula; Anastasia Nikolopoulou; John W Babich; Joseph R Osborne; Scott T Tagawa; Irina Lipai; Lilja Solnes; Kevin P Maresca; Thomas Armor; John L Joyal; Robert Crummet; James B Stubbs; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2014-10-23       Impact factor: 10.057

3.  Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.

Authors:  Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

Review 4.  Novel tracers and their development for the imaging of metastatic prostate cancer.

Authors:  Andrea B Apolo; Neeta Pandit-Taskar; Michael J Morris
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

5.  (68)Ga generator integrated system: elution-purification-concentration integration.

Authors:  Van So Le
Journal:  Recent Results Cancer Res       Date:  2013

6.  Prostate-specific membrane antigen expression in normal and malignant human tissues.

Authors:  D A Silver; I Pellicer; W R Fair; W D Heston; C Cordon-Cardo
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

7.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors:  A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-24       Impact factor: 9.236

8.  Exogenous Molecular Probes for Targeted Imaging in Cancer: Focus on Multi-modal Imaging.

Authors:  Bishnu P Joshi; Thomas D Wang
Journal:  Cancers (Basel)       Date:  2010-06-11       Impact factor: 6.639

9.  GMP-compliant (68)Ga radiolabelling in a conventional small-scale radiopharmacy: a feasible approach for routine clinical use.

Authors:  Roeland Vis; Jules Lavalaye; Ewoudt Mw van de Garde
Journal:  EJNMMI Res       Date:  2015-04-24       Impact factor: 3.138

Review 10.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

View more
  6 in total

1.  Theranostics in India: a Particularly Exquisite Concept or an Experimental Tool.

Authors:  Partha S Choudhury; Manoj Gupta
Journal:  Nucl Med Mol Imaging       Date:  2019-01-23

2.  Targeting integrin αvβ6 with gallium-68 tris (hydroxypyridinone) based PET probes.

Authors:  Giuseppe Floresta; Siham Memdouh; Truc Pham; Michelle T Ma; Philip J Blower; Robert C Hider; Vincenzo Abbate; Agostino Cilibrizzi
Journal:  Dalton Trans       Date:  2022-08-30       Impact factor: 4.569

3.  68Ga-Chelation and comparative evaluation of N,N'-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid (HBED-CC) conjugated NGR and RGD peptides as tumor targeted molecular imaging probes.

Authors:  Drishty Satpati; Rohit Sharma; Chandan Kumar; Haladhar Dev Sarma; Ashutosh Dash
Journal:  Medchemcomm       Date:  2017-02-16       Impact factor: 3.597

Review 4.  Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?

Authors:  Nicolas Lepareur
Journal:  Front Med (Lausanne)       Date:  2022-02-10

5.  Quality control and GMP synthesis of 68Ga-prostate-specific membrane antigen-11 for detection of low- and high-grade prostate cancer.

Authors:  Majid Assadi; Habibollah Dadgar
Journal:  World J Nucl Med       Date:  2019-07-23

Review 6.  Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents.

Authors:  Marcin Czarniecki; Esther Mena; Liza Lindenberg; Marek Cacko; Stephanie Harmon; Jan Philipp Radtke; Frederick Giesel; Baris Turkbey; Peter L Choyke
Journal:  Transl Androl Urol       Date:  2018-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.